The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

During an FDA panel discussion, the US health secretary prioritised easier routes to market for curative therapies.

Fintel reports that on June 6, 2025, Scotiabank upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Sector ...

The Platform Technology Designation, which predates the current FDA leadership, is designed to streamline the drug ...

Sarepta Therapeutics (SRPT) stock gains as Scotiabank upgrades it to Sector Outperform ting a compelling risk-reward setup. Read more here.

US rare disease meds developer Sarepta Therapeutics (Nasdaq: SRPT) revealed that its rAAVrh74 viral vector used in the ...

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation: Cambridge, Massachusetts Friday, June 6, 2025, ...

The S&P 500 Index ($SPX) (SPY) today is up +1.23%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +1.34%, and the Nasdaq ...

RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Explore Sarepta Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for SRPT. Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade ...